arrow
D

David McGuinness

AstraZeneca
H指数:28
被引数:4,875

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial

在PROpel试验中,奥拉帕利联合阿比特龙与安慰剂联合阿比特龙治疗转移性去势抵抗性前列腺癌非BRCA突变亚组患者的有效性与安全性比较

2026-10-050
OAAI
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study

在PROpel III期研究中,接受奥拉帕利联合阿比特龙治疗或安慰剂联合阿比特龙治疗转移性去势抵抗性前列腺癌患者的患者报告结局。

2025-11-170
OAAI
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial

奥拉帕利联合阿比特龙对比安慰剂联合阿比特龙在无症状/轻度症状及症状性转移性去势抵抗性前列腺癌患者一线治疗中的有效性和安全性:来自III期PROpel试验的分析

2024-10-010
OAAI
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
2019-12-0134
OAAI